TY - JOUR
T1 - Toxicity of Immune Checkpoint Inhibitors
T2 - Considerations for the Surgeon
AU - Helmink, Beth A.
AU - Roland, Christina L.
AU - Kiernan, Colleen M.
AU - Wargo, Jennifer A.
N1 - Funding Information:
Beth A. Helmink, MD, PhD, was supported by National Institutes of Health T32 CA 009599 and the MD Anderson Cancer Center support Grant (P30 CA016672). Colleen M. Kiernan, MD, MPH, reports no disclosures. Christina L. Roland, MD, MS, receives research support from Bristol Myers Squibb. Jennifer A. Wargo, MD, MSc, reports compensation for speaker’s bureau and honoraria from Imedex, Dava Oncology, Omniprex, Illumina, Gilead, PeerView, Physician Education Resource, MedImmune, Exelixis, and Bristol-Myers Squibb. She serves as a consultant/advisory board member for Roche/Genentech, Novartis, AstraZeneca, GlaxoSmithKline, Bristol-Myers Squibb, Merck, Biothera Pharmaceuticals, and Microbiome DX; receives research support from GlaxoSmithKline, Roche/Genentech, Bristol-Myers Squibb, and Novartis; and has a U.S. patent application (PCT/US17/53.717) submitted by the University of Texas MD Anderson Cancer Center that covers methods to enhance immune checkpoint blockade responses by modulating the microbiome.
Publisher Copyright:
© 2020, Society of Surgical Oncology.
PY - 2020/5/1
Y1 - 2020/5/1
N2 - Background: The use of immunotherapeutic agents, specifically immune checkpoint inhibitors (ICIs) for solid malignancies, is rapidly rising, and many new agents and treatment combinations are in development. However, ICIs have a unique side-effect profile of immune-related adverse events (irAEs) compared with chemotherapeutic agents or targeted therapies. Methods: In this report the diverse spectrum of irAEs is highlighted using two patients with metastatic melanoma undergoing treatment with ICIs. We supplement these case reports with a brief literature review of the data regarding the safety of surgical intervention in patients taking irAEs. Results: The report describes the basic approach to the detection and management of irAEs, notes important perioperative considerations, and discusses the safety of surgical intervention for these patients. Conclusions: Overall, these irAEs represent a diverse group of pathologies with variable timing and sometimes subtle presentation requiring careful monitoring and heightened clinical suspicion for potential toxicity by all providers, including surgeons.
AB - Background: The use of immunotherapeutic agents, specifically immune checkpoint inhibitors (ICIs) for solid malignancies, is rapidly rising, and many new agents and treatment combinations are in development. However, ICIs have a unique side-effect profile of immune-related adverse events (irAEs) compared with chemotherapeutic agents or targeted therapies. Methods: In this report the diverse spectrum of irAEs is highlighted using two patients with metastatic melanoma undergoing treatment with ICIs. We supplement these case reports with a brief literature review of the data regarding the safety of surgical intervention in patients taking irAEs. Results: The report describes the basic approach to the detection and management of irAEs, notes important perioperative considerations, and discusses the safety of surgical intervention for these patients. Conclusions: Overall, these irAEs represent a diverse group of pathologies with variable timing and sometimes subtle presentation requiring careful monitoring and heightened clinical suspicion for potential toxicity by all providers, including surgeons.
KW - Checkpoint blockade
KW - Immunotherapy
KW - Melanoma
KW - Surgery
UR - http://www.scopus.com/inward/record.url?scp=85078192796&partnerID=8YFLogxK
U2 - 10.1245/s10434-019-08183-0
DO - 10.1245/s10434-019-08183-0
M3 - Article
C2 - 31965370
AN - SCOPUS:85078192796
SN - 1068-9265
VL - 27
SP - 1533
EP - 1545
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 5
ER -